Cite
Quality of life (QoL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC).
MLA
Láng, I., et al. “Quality of Life (QoL) Results from the TURANDOT Trial Comparing Two Bevacizumab (BEV)-Containing Regimens as First-Line Treatment for HER2-Negative Metastatic Breast Cancer (MBC).” Cancer Research, vol. 72, no. 24a, Dec. 2012, pp. 1609–10. EBSCOhost, https://doi.org/10.1158/0008-5472.SABCS12-P5-17-03.
APA
Láng, I., Inbar, M. J., Kahan, Z., Greil, R., Beslija, S., Stemmer, S. M., Kaufman, B., Ahlers, S., Brodowicz, T., & Zielinski, C. (2012). Quality of life (QoL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research, 72(24a), 1609–1610. https://doi.org/10.1158/0008-5472.SABCS12-P5-17-03
Chicago
Láng, I., M. J. Inbar, Z. Kahan, R. Greil, S. Beslija, S. M. Stemmer, B. Kaufman, S. Ahlers, T. Brodowicz, and C. Zielinski. 2012. “Quality of Life (QoL) Results from the TURANDOT Trial Comparing Two Bevacizumab (BEV)-Containing Regimens as First-Line Treatment for HER2-Negative Metastatic Breast Cancer (MBC).” Cancer Research 72 (24a): 1609–10. doi:10.1158/0008-5472.SABCS12-P5-17-03.